Age: From 18 years old
Gender: Female or Male
Duration: Up to 52 weeks approximately For patients with active psoriatic arthritis
Compensation: Up to $2,425
About this study:
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experienced Subjects with Active Psoriatic Arthritis I (INSPIRE 1) To evaluate the tildrakizumab compared to placebo in anti-tumor necrosis factor (TNF) experienced subjects with active psoriatic arthritis (PsA) as measured by the proportion of subjects achieving a 20% reduction from baseline in American College of Rheumatology response criteria [ACR20].
Who can participate?
Adult subjects with a clinical diagnosis of active PsA with joint symptoms present for at least 6 months, and ≥ 3 tender and ≥ 3 swollen joints and prior anti-TNF agent exposure at screening and baseline will be enrolled in the study.
Where is the study taking place?
The study is being conducted at our facility in Palmetto Medical Plaza.
NCT04314544
